Equity Briefing: Healthcare Review - KERX, MAKO, OMPI, CHTP, IART and OSUR Move
(Thomson Reuters ONE) -
U.S. stocks are traded within a narrow range after the recent earnings sell off.
Several healthcare/biotech stocks showed unusual movement in Tuesday's trading
including MAKO Surgical and Chelsea Therapeutics.
Keryx Biopharmaceuticals (NASDAQ:KERX) stock gained 5.94% to $2.14 +0.12 after
the company announced that Ron Bentsur, the Company's Chief Executive Officer,
will be presenting at the 7th Annual JMP Securities Healthcare Conference, being
held July 12-13, 2012, in New York City. Mr. Bentsur's presentation is scheduled
to take place on Friday, July 13, 2012 at 12:00 noon Eastern Time.
MAKO Surgical Corp. (NASDAQ:MAKO) stock plunged -43.07% to $14.01 -10.60 after
the company said it expects to sell fewer RIO robotic arm orthopedic systems
this year, less than forecast. The company currently expects to sell 42 to 48
Rio systems in 2012, down from its May projection of 52 to 58 for the year. The
company's robotic arm is proposed to allow orthopedic surgeons to achieve
greater precision.
Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) shares declined to $1.11-
0.13 (-10.48%) after the company announced that its Board of Directors plans to
promptly implement a corporate reorganization that includes a reduction in
force, executive changes and changes to the Company's Board of Directors, and
has authorized a plan to explore and evaluate strategic options for the Company,
all with the goal of optimizing long-term stockholder value. Last week we
reported that the stock had surged, but only as the apparent result of paid
promotional activities by a group of stock promoters.
Shares of Obagi Medical Products (NASDAQ:OMPI) surged to a high of $19 after the
market close following an 8K filing that appears to firmly set the table for the
company's acquisition. On Monday, Cantor Fitzgerald's Irina Rivkind confirmed
what others had been saying for months. The analyst said the company could be
attractive to "multiple suitors." In a note to clients, she also called Obagi
attractive given its "brand recognition" and reputation for efficacy. The
analyst also pointed to the company's pristine balance sheet and "healthy"
growth. Speculators are expecting a buy-out north of $22 per share, but heavy
covering could force shares even higher.
Integra Lifesciences Holdings Corp (NASDAQ:IART) shares gained 5.03% to $38.61
+1.85 after the company said it will release its second quarter 2012 financial
results on Thursday, July 26, 2012. The company has scheduled a conference call
for 8:30 AM ET the same day to discuss the results. The company's senior
management team will host the conference call, which will be open to all
listeners.
OraSure Technologies, Inc. (NASDAQ:OSUR) stock fell to $12.34 -1.04 (-7.77%)
after the company announced it has commenced an underwritten public offering of
its common stock in an amount of up to $75.0 million. Citigroup and Jefferies
are acting as joint book-running managers. The Company expects to grant the
underwriters a 30-day option to purchase up to an additional 15% of the shares
of common stock offered in the public offering.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Equity Briefing via Thomson Reuters ONE
[HUG#1625781]
Datum: 11.07.2012 - 08:03 Uhr
Sprache: Deutsch
News-ID 164150
Anzahl Zeichen: 3966
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 102 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Equity Briefing: Healthcare Review - KERX, MAKO, OMPI, CHTP, IART and OSUR Move"
steht unter der journalistisch-redaktionellen Verantwortung von
Equity Briefing (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
